Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.37 |
| ▸ | GPR3 | P46089 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 5/20 | 0.36 |
| ▸ | RAB9A | P51151 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | PRNP | P04156 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2092333 | 0.77 | HDAC3 (0.50) | SLC9A1ALDH1A1GPR3HPGDMEN1 | |
| SCHEMBL2090965 | 0.77 | PLAU (0.51) | SLC9A1ALDH1A1SMN1; SMN2GPR3HPGD | |
| SCHEMBL2091915 | 0.77 | SLC9A1 (0.45) | SLC9A1ALDH1A1SMN1; SMN2GPR3HPGD | |
| SCHEMBL5504564 | 0.76 | SLC9A1 (0.50) | SLC9A1ALDH1A1POLBSMN1; SMN2GPR3 | |
| SCHEMBL2403651 | 0.76 | SLC9A1 (0.45) | SLC9A1ALDH1A1POLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL27718654 | 0.74 | SLC9A1 (0.44) | SLC9A1ALDH1A1POLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL27552551 | 0.74 | ALDH1A1 (0.52) | SLC9A1ALDH1A1POLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL146453 | 0.74 | ALDH1A1 (0.52) | SLC9A1ALDH1A1POLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL2096283 | 0.74 | SLC9A1 (0.41) | SLC9A1ALDH1A1POLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL5534903 | 0.72 | KDM4E (0.36) | SLC9A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3101017-B1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2019-06-12 | — | — | EP | claimed |
| EP-3101017-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2016-12-07 | — | — | EP | claimed |
| EP-2142534-B1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2016-08-10 | — | — | EP | claimed |
| US-20160024048-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2016-01-28 | — | — | US | claimed |
| US-8153659-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2012-04-10 | — | — | US | claimed |
| EP-2142534-A2 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2010-01-13 | — | — | EP | claimed |
| US-20090004209-A1 | 4'-O- substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION | 2009-01-01 | — | — | US | claimed |
| WO-2008115516-A2 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2008-09-25 | — | — | WO | claimed |
| US-20200113896-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARM LLC (US) | 2020-04-16 | — | — | US | disclosed |
| US-10385037-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2019-08-20 | — | — | US | disclosed |
| EP-3101017-B1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2019-06-12 | — | — | EP | disclosed |
| CN-105358177-B | Combination therapy comprising TOR kinase inhibitor and IMID compound for treating cancer | 西格诺药品有限公司 | 2018-11-23 | — | — | CN | disclosed |
| US-20180155316-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2018-06-07 | — | — | US | disclosed |
| US-9920027-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| CN-1878777-A | 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2006-12-13 | — | — | CN | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | SLC9A1 2413/4885ALDH1A1 355/4885POLB 1637/4885 |
| US-20200113896-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | MTOR, ULK1, RICTOR | SLC9A1 3911/4885ALDH1A1 4213/4885POLB 2035/4885 |
| US-20160024048-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A4, CYP3A7, CYP4B1 | SLC9A1 2893/4885ALDH1A1 1376/4885POLB 1146/4885 |
| US-20090004209-A1 | 4'-O- substituted isoindoline derivatives and compositions comprising and methods of using the same | CYP3A4, CYP3A7, CYP4B1 | SLC9A1 2893/4885ALDH1A1 1376/4885POLB 1146/4885 |
| US-20180155316-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A4, CYP3A7, CYP4B1 | SLC9A1 2893/4885ALDH1A1 1376/4885POLB 1146/4885 |
| US-10385037-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CYP3A4, CYP3A7, CYP4B1 | SLC9A1 2996/4885ALDH1A1 1450/4885POLB 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.